Can a 3-Day course shift mental health care toward recovery?

NCT ID NCT05824234

Recruiting now Knowledge-focused Sponsor: Hôpital le Vinatier Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether a 3-day training program called REFOCUS helps mental health teams provide care that supports personal recovery. About 760 people with severe mental disorders (like schizophrenia or bipolar disorder) will take part across 18 centers. Researchers will measure changes in patients' recovery progress and staff practices.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: REFOCUS training program (a 3-day course for mental health teams)
What this could lead to: If successful, this could show that training staff in recovery-oriented care improves patient outcomes and well-being.
What could go wrong: This is an early-stage implementation study, not a drug trial. Results depend on how well teams adopt the training, and benefits may vary across settings.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BIPOLAR DISORDER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

anxiety disorder bipolar disorder borderline personality disorder depressive disorder major depressive disorder mental disorder psychiatric disorder schizoaffective disorder schizophrenia schizophreniform disorder schizotypal personality disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MENTAL DISORDERS

Contacts and locations

Locations

centre de réhabilitation - Hôpital le Vinatier
RECRUITING

Lyon, Rhône, 69006, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.